Your browser doesn't support javascript.
Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines.
Marking, Ulrika; Havervall, Sebastian; Greilert-Norin, Nina; Ng, Henry; Blom, Kim; Nilsson, Peter; Phillipson, Mia; Hober, Sophia; Nilsson, Charlotta; Mangsbo, Sara; Christ, Wanda; Klingström, Jonas; Gordon, Max; Åberg, Mikael; Thålin, Charlotte.
  • Marking U; Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, 182 88 Stockholm, Sweden.
  • Havervall S; Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, 182 88 Stockholm, Sweden.
  • Greilert-Norin N; Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, 182 88 Stockholm, Sweden.
  • Ng H; Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, 182 88 Stockholm, Sweden.
  • Blom K; Department of Medical Cell Biology, Uppsala University, 751 23 Uppsala, Sweden.
  • Nilsson P; Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, 182 88 Stockholm, Sweden.
  • Phillipson M; Department of Microbiology, Public Health Agency of Sweden, 171 82 Solna, Sweden.
  • Hober S; Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, 114 28 Stockholm, Sweden.
  • Nilsson C; Department of Medical Cell Biology, Uppsala University, 751 23 Uppsala, Sweden.
  • Mangsbo S; Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, 114 28 Stockholm, Sweden.
  • Christ W; Department of Microbiology, Public Health Agency of Sweden, 171 82 Solna, Sweden.
  • Klingström J; Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, 171 76 Stockholm, Sweden.
  • Gordon M; Department of Pharmacy, SciLifeLab, Uppsala University, 751 23 Uppsala, Sweden.
  • Åberg M; Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, 141 52 Stockholm, Sweden.
  • Thålin C; Department of Microbiology, Public Health Agency of Sweden, 171 82 Solna, Sweden.
Vaccines (Basel) ; 10(3)2022 Feb 24.
Article in English | MEDLINE | ID: covidwho-1726057
ABSTRACT
Heterologous primary immunization against SARS-CoV-2 is part of applied recommendations. However, little is known about duration of immune responses after heterologous vaccine regimens. To evaluate duration of immune responses after primary vaccination with homologous adeno-vectored ChAdOx1 nCoV-19 vaccine (ChAd) or heterologous ChAd/BNT162b2 mRNA vaccine (BNT), anti-spike-IgG and SARS-CoV-2 VOC-neutralizing antibody responses were measured in 354 healthcare workers (HCW) at 2 weeks, 3 months, 5 months and 6 months after the second vaccine dose. T-cell responses were investigated using a whole blood interferon gamma (IFN-γ) release assay 2 weeks and 3 months post second vaccine dose. Two hundred and ten HCW immunized with homologous BNT were enrolled for comparison of antibody responses. In study participants naïve to SARS-CoV-2 prior to vaccination, heterologous ChAd/BNT resulted in 6-fold higher peak anti-spike IgG antibody titers compared to homologous ChAd vaccination. The half-life of antibody titers was 3.1 months (95% CI 2.8-3.6) following homologous ChAd vaccination and 1.9 months (95% CI 1.7-2.1) after heterologous vaccination, reducing the GMT difference between the groups to 3-fold 6 months post vaccination. Peak T-cell responses were stronger in ChAd/BNT vaccinees, but no significant difference was observed 3 months post vaccination. SARS-CoV-2 infection prior to vaccination resulted in substantially higher peak GMTs and IFN-γ levels and enhanced SARS-CoV-2 specific antibody and T cell responses over time. Heterologous primary SARS-CoV-2 immunization with ChAd and BNT elicits a stronger initial immune response compared to homologous vaccination with ChAd. However, although the differences in humoral responses remain over 6 months, the difference in SARS-CoV-2 specific T cell responses are no longer significant three months after vaccination.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines / Variants Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10030359

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines / Variants Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10030359